SER Serina Therapeutics, Inc.
Price Chart
Executive Summary
Two Serina directors made small open-market purchases totaling ~$38K in the 7-day window ending May 22, 2026. These trades follow the Q1 2026 earnings release (PIPE-funded, cash runway extended to $24.5M) and precede the S-3 resale registration filed May 22 that enables selling stockholders — including an insider — to unload shares from the same PIPE. At just ~0.13% of the $30M market cap, the dollar value is trivial relative to the company's size and the overwhelming dilution signal from the S-3 cross-filing context (which was rated bearish 7/10). The cluster buys do not offset that far larger capital-structure event.
Key Financial Metrics
Actionable Insight
The small director buys are noise. The S-3 resale registration (bearish 7/10 impact) is the dominant signal — selling stockholders including an insider are positioned to exit, and the company has going-concern risk with recurring operating losses. Traders should expect downward pressure as the resale shares work into the market. Ignore the $38K buy signal.
Key Facts
- Two directors (Wilson and Marshall) purchased a total of ~22.2K shares at $1.65-$1.93 for aggregate ~$38K in the 7-day window ending May 22, 2026.
- Total insider spend ($38K) represents ~0.13% of SER's $30M market cap — disproportionate to the company's fundamental and capital-structure news in the same period.
- On May 14, Serina reported Q1 2026 net loss of -$6.9M (vs -$4.8M YoY), cash of $24.5M post-PIPE, and disclosed its Phase 1b registrational study of SER-252 is under way.
- On May 22, Serina filed an S-3 registering up to 16.45M shares for resale by selling stockholders — potential dilution exceeding 100% of the 14.9M shares outstanding.
- The S-3 covers PIPE shares and includes insider Dr. Gregory H. Bailey as a selling stockholder, creating a conflict with the small director purchases.
- Historical performance for SER reports shows 0% win rate at T+20 across 4 settled reports with average alpha vs SPY of -28.55% — traders have consistently over-estimated positive catalysts for this name.
Financial Impact
Insider purchases of ~$38K are trivial vs $30M market cap; the S-3 resale registration carries potential dilution of $16.45M shares (109% of current float) against a cash balance of $24.5M.
Risk Factors
- S-3 resale shares enable selling stockholders (including an insider) to liquidate, creating persistent overhang and likely share price depreciation.
- Q1 2026 net loss widened to -$6.9M from -$4.8M YoY with no revenue; cash burn continues against a narrow cash runway even after the $21.2M PIPE.
- Phase 1b data for SER-252 (TFL from SAD arm) not expected until H1 2027 — no near-term catalyst to offset dilution.
- Historical SER reports have 0% win rate at T+20; the stock has consistently underperformed after prior neutral/bullish filings, suggesting systematic over-optimism.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SER-1779827227316 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
9d ago
|
EFFECT
| $1.86 $1.88 | ▼ −1.08% | ▼ −3.67% | $1.84 (+1.08%) |
|
May 26, 2026
17d ago
|
Insider Cluster
| $1.80 $1.95 | ▲ +8.33% | ▲ +7.78% | $1.84 (+2.22%) |
|
May 26, 2026
17d ago
|
Insider Cluster
| $1.80 $1.95 | ▼ −8.33% | ▼ −7.78% | $1.84 (−2.22%) |
|
May 22, 2026
21d ago
|
S-3
| $1.92 $1.86 | ▲ +3.13% | ▲ +3.08% | $1.84 (+4.17%) |
|
Mar 27, 2026
11w ago
|
10-K/A
| $2.27 $1.80 | ▼ −20.70% | ▼ −20.35% | $1.84 (−18.94%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $2.61 $2.27 | ▼ −13.03% | ▼ −11.35% | $1.84 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access